{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:45:42Z","timestamp":1792478742463,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.immuni.2015.12.003","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T06:50:32Z","timestamp":1450335032000},"page":"1040-1051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":456,"title":["Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions"],"prefix":"10.1016","volume":"43","author":[{"given":"Dhavalkumar\u00a0D.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay\u00a0K.","family":"Kuchroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2015.12.003_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaci.2009.05.004","article-title":"Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome","volume":"124","author":"Al Khatib","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.immuni.2015.12.003_bib2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm.3268","article-title":"How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases","volume":"19","author":"Baeten","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.20042279","article-title":"IL-12- and IL-23-induced T helper cell\u00a0subsets: birds of the same feather flock together","volume":"201","author":"Bettelli","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T\u00a0cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1086\/302765","article-title":"Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein","volume":"66","author":"Bj\u00f6rses","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.immuni.2015.12.003_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.immuni.2013.09.002","article-title":"An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis","volume":"39","author":"Boisson","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib7","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/cmi.2012.1","article-title":"Dectin-1 isoforms contribute to distinct Th1\/Th17 cell activation in mucosal candidiasis","volume":"9","author":"Carvalho","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2012.09.016","article-title":"A validated regulatory network for Th17 cell specification","volume":"151","author":"Ciofani","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2015.12.003_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1084\/jem.20080321","article-title":"Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T\u00a0cells","volume":"205","author":"de Beaucoudrey","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MD.0b013e3181fdd832","article-title":"Revisiting human IL-12R\u03b21 deficiency: a survey of 141 patients from 30 countries","volume":"89","author":"de Beaucoudrey","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.immuni.2015.12.003_bib13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.immuni.2015.12.003_bib14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2012-08-450551","article-title":"Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency","volume":"121","author":"Drewniak","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2015.12.003_bib15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.12.003_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/ard.2007.072819","article-title":"Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis","volume":"67","author":"Farag\u00f3","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/ar4428","article-title":"The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing","volume":"16","author":"Felson","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.immuni.2015.12.003_bib18","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.4049\/jimmunol.170.4.2106","article-title":"IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger","volume":"170","author":"Ferretti","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.immuni.2015.12.003_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-\u03b2 signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2015.12.003_bib27","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib28","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.immuni.2015.12.003_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/jid.2008.233","article-title":"Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis","volume":"129","author":"H\u00fcffmeier","year":"2009","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/pathogens4030559","article-title":"Neutrophils Do Not Express IL-17A in the Context of Acute Oropharyngeal Candidiasis","volume":"4","author":"Huppler","year":"2015","journal-title":"Pathogens"},{"key":"10.1016\/j.immuni.2015.12.003_bib31","doi-asserted-by":"crossref","first-page":"e003","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.immuni.2015.12.003_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.immuni.2015.12.003_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.immuni.2015.12.003_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib40","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib42","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2015.12.003_bib43","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.immuni.2015.12.003_bib44","doi-asserted-by":"crossref","first-page":"e1000041","DOI":"10.1371\/journal.pgen.1000041","article-title":"A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci","volume":"4","author":"Liu","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.immuni.2015.12.003_bib45","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm0502-500","article-title":"Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis","volume":"8","author":"Lock","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib47","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1084\/jem.20080218","article-title":"Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3","volume":"205","author":"Ma","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib49","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib50","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nature06764","article-title":"Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome","volume":"452","author":"Milner","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.immuni.2015.12.003_bib54","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T\u00a0cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib55","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2015.12.003_bib56","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T\u00a0cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1517\/13543784.2015.1035432","article-title":"Inflammatory bowel disease therapies discontinued between 2009 and 2014","volume":"24","author":"Mozaffari","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.immuni.2015.12.003_bib58","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T\u00a0cell-mediated intestinal inflammation","volume":"10","author":"O\u2019Connor","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib60","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.12.003_bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ni.2089","article-title":"IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium","volume":"12","author":"Ota","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib62","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/cid\/cit722","article-title":"Clinical features of Candidiasis in patients with inherited interleukin 12 receptor \u03b21 deficiency","volume":"58","author":"Ouederni","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib63","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2015.12.003_bib64","first-page":"706","article-title":"Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J.\u00a0Drugs Dermatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.141271","article-title":"A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"42","author":"Pavelka","year":"2015","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib66","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.immuni.2011.10.015","article-title":"Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation","volume":"35","author":"Peters","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib67","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1086\/604714","article-title":"Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients","volume":"49","author":"Plantinga","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib68","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MD.0b013e31828a01f9","article-title":"Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds","volume":"92","author":"Prando","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.immuni.2015.12.003_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1084\/jem.20091983","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.12.003_bib72","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.23389","article-title":"Association of interleukin-23 receptor variants with ankylosing spondylitis","volume":"58","author":"Rahman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.immuni.2015.12.003_bib73","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni.2053","article-title":"The development of inducible bronchus-associated lymphoid tissue depends on IL-17","volume":"12","author":"Rangel-Moreno","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib74","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib75","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T\u00a0cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib76","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib77","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.immuni.2015.12.003_bib78","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T\u00a0cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"issue":"Suppl 2","key":"10.1016\/j.immuni.2015.12.003_bib79","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib80","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/ni.2797","article-title":"Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR\u03b3t and dectin-2","volume":"15","author":"Taylor","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib81","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib82","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.immuni.2015.12.003_bib83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1100102","article-title":"STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis","volume":"365","author":"van de Veerdonk","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.12.003_bib84","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de\u00a0novo differentiation of IL-17-producing T\u00a0cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib85","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ni.2479","article-title":"The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90","volume":"14","author":"Wang","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.12.003_bib86","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/MIB.0000000000000353","article-title":"Neutralizing IL-23 is superior to blocking IL-17 in suppressing intestinal inflammation in a spontaneous murine colitis model","volume":"21","author":"Wang","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.immuni.2015.12.003_bib87","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.immuni.2006.06.002","article-title":"Th17: an effector CD4 T\u00a0cell lineage with regulatory T\u00a0cell ties","volume":"24","author":"Weaver","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.12.003_bib88","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature11984","article-title":"Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1","volume":"496","author":"Wu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib89","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature11981","article-title":"Dynamic regulatory network controlling TH17 cell differentiation","volume":"496","author":"Yosef","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.12.003_bib90","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-\u03b3 or IL-10 and are regulated by IL-1\u03b2","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107476131500504X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107476131500504X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T01:41:29Z","timestamp":1692150089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107476131500504X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S107476131500504X"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2015.12.003","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2015.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}